Ignite Creation Date:
2024-05-05 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00369967
Status:
TERMINATED
Last Update Posted:
2016-07-22
First Post:
2006-08-29
Brief Title:
Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents
Sponsor:
Virginia Commonwealth University
Organization:
Virginia Commonwealth University
Study Overview
Official Title:
Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents A Randomized Controlled Trial
Status:
TERMINATED
Status Verified Date:
2016-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
difficulty in subject recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We hypothesize that using quick start initiation of the contraceptive vaginal ring in adolescents seeking birth control will improve compliance compared to traditional start We will conduct a randomized controlled trial comparing quick start to traditional start initiation of the contraceptive vaginal ring in adolescents seeking birth control The primary study outcome is method continuation at 3 6 and 12 months Secondary outcomes include abnormal bleeding product satisfaction and adverse events
Detailed Description:
Pregnancy prevention is an important aspect of adolescent healthcare Adherence to a chosen contraception method is essential to its success Adolescents are notoriously poor at complying with oral contraceptives OCs with continuation rates at one year as low as 12 1 In those patients who continue their contraceptive method our best data estimates that the average OC user misses three pills per cycle 2 Given the already highly fluctuant serum hormone levels in OC users 3 this leaves poorly compliant users at greater risk for unintended pregnancy
The contraceptive vaginal ring is a reliable method of contraception and may be particularly useful in the adolescent population because of its simple monthly dosing schedule 4 It is a combined hormonal contraceptive containing etonogestrel a progesterone and ethinyl estradiol an estrogen which are released continuously at low levels The vaginal ring has been shown to have comparable efficacy and tolerability to OCs 5 but does not require daily dosing due to its novel drug delivery system Studies have shown high rates of acceptability and satisfaction with vaginal ring usage in adult and adolescent women and a high rate of continuation using a traditional start method 6
The quick start method of initiating use of OCs has been found to improve continuation rates and overall method satisfaction compared to traditional start in large studies of adult women 7 and also in small studies of adolescents 8 without significantly affecting incidence of breakthrough bleeding or patient satisfaction 9 Quick start contraceptive vaginal ring has been studied in women aged 18-40 years and found to have a more favorable bleeding profile than quick start Ortho-Tricyclen Lo 10 This decreased incidence of altered bleeding may be a more favorable benefit of quick start contraceptive vaginal ring in the adolescent population as well
One of the biggest obstacles to use of the contraceptive vaginal ring in clinical practice is having the patient overcome the idea of vaginally inserting the ring especially in the adolescent population 11 It seems logical that initiating the vaginal ring in the office via the quick start method may improve patient acceptance and comfort with the method thus improving continuation rates in these patients compared to traditional initiation
We propose to perform a randomized controlled trial comparing quick start to traditional start NuvaRing in adolescents Subjects meeting inclusion criteria will be randomized to either start the method in the office immediately or start the method within 5 days of her next menstrual period Subjects will follow up at 3 6 and 12 months at which time we will assess continuation bleeding patterns pregnancy and patient satisfaction
The contraceptive vaginal ring is a reliable method of contraception and may be particularly useful in the adolescent population because of its simple monthly dosing schedule 4 It is a combined hormonal contraceptive containing etonogestrel a progesterone and ethinyl estradiol an estrogen which are released continuously at low levels The vaginal ring has been shown to have comparable efficacy and tolerability to OCs 5 but does not require daily dosing due to its novel drug delivery system Studies have shown high rates of acceptability and satisfaction with vaginal ring usage in adult and adolescent women and a high rate of continuation using a traditional start method 6
The quick start method of initiating use of OCs has been found to improve continuation rates and overall method satisfaction compared to traditional start in large studies of adult women 7 and also in small studies of adolescents 8 without significantly affecting incidence of breakthrough bleeding or patient satisfaction 9 Quick start contraceptive vaginal ring has been studied in women aged 18-40 years and found to have a more favorable bleeding profile than quick start Ortho-Tricyclen Lo 10 This decreased incidence of altered bleeding may be a more favorable benefit of quick start contraceptive vaginal ring in the adolescent population as well
One of the biggest obstacles to use of the contraceptive vaginal ring in clinical practice is having the patient overcome the idea of vaginally inserting the ring especially in the adolescent population 11 It seems logical that initiating the vaginal ring in the office via the quick start method may improve patient acceptance and comfort with the method thus improving continuation rates in these patients compared to traditional initiation
We propose to perform a randomized controlled trial comparing quick start to traditional start NuvaRing in adolescents Subjects meeting inclusion criteria will be randomized to either start the method in the office immediately or start the method within 5 days of her next menstrual period Subjects will follow up at 3 6 and 12 months at which time we will assess continuation bleeding patterns pregnancy and patient satisfaction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None